1999
Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia
Jillella A, Doria R, Khan K, Zelterman D, Ahmad Y, Smith B, Holmes W, Becker P, Roberts K, Rappeport J. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplantation 1999, 23: 1095-1100. PMID: 10382947, DOI: 10.1038/sj.bmt.1701786.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationTotal body irradiationBone marrow transplantationConditioning regimenMarrow transplantationMyeloablative regimenRelapse rateBody irradiationHematologic malignanciesAntileukemic effectGood prognosis diseaseHigh-dose cytosineHost disease (GVHD) prophylaxisShort-course methotrexateEvidence of diseaseOverall relapse rateHigh-dose AraPoor prognosis diseaseKaplan-Meier estimatesActuarial survivalConditioning regimensDisease prophylaxisMyeloablative regimensProspective studyRegimen
1994
B-Cell Precursor Bone Marrow Reconstitution After Bone Marrow Transplantation
Leitenberg D, Rappeport J, Smith B. B-Cell Precursor Bone Marrow Reconstitution After Bone Marrow Transplantation. American Journal Of Clinical Pathology 1994, 102: 231-236. PMID: 8042594, DOI: 10.1093/ajcp/102.2.231.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CDB-LymphocytesBlotting, SouthernBone MarrowBone Marrow CellsBone Marrow TransplantationChildChild, PreschoolClone CellsFemaleFlow CytometryFluorescent Antibody TechniqueGene Rearrangement, B-Lymphocyte, Heavy ChainHematopoietic Stem CellsHumansImmunophenotypingInfantKineticsMaleMiddle AgedNeprilysinConceptsBone marrow transplantationMarrow transplantationB cell subsetsBone marrow reconstitutionB cell precursorsSurface antigenic phenotypeImmature B cellsImmunoglobulin gene rearrangementsHumoral immunodeficiencyMonoclonal gammapathyMarrow reconstitutionAntigenic phenotypeB cellsTransplantationGene rearrangementsMarked increaseLeukemia lymphoblastsCellsPatientsGammapathyImmunodeficiencyMarrowCD34ReconstitutionMonths
1992
Pharmacology of agents used in bone marrow transplant conditioning regimens
Wiebe V, Smith B, DeGregorio M, Rappeport J. Pharmacology of agents used in bone marrow transplant conditioning regimens. Critical Reviews In Oncology/Hematology 1992, 13: 241-270. PMID: 1476655, DOI: 10.1016/1040-8428(92)90092-5.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBone Marrow TransplantationBusulfanCarmustineHematopoiesisHumansImmunosuppressive AgentsMelphalanWhole-Body IrradiationConceptsBone marrow transplantationTotal body irradiationConditioning regimensPharmacology of agentsSingle fraction total body irradiationTransplant conditioning regimensTransplantation conditioning regimensConditioning regimentEffective immunosuppressionTBI regimensBody irradiationMarrow transplantationCurative potentialEngraftment rateDonor histocompatibilityToxicity profilePharmacologic behaviorRegimensAntineoplastic propertiesHematopoietic spaceAntineoplastic activityDisease statesPharmacology
1990
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. Journal Of Clinical Oncology 1990, 8: 648-56. PMID: 2313334, DOI: 10.1200/jco.1990.8.4.648.Peer-Reviewed Original ResearchConceptsAutologous bone marrow transplantationMaximum-tolerated doseBone marrow transplantationRelapsed lymphomaComplete responseMarrow transplantationDose levelsVP-16Refractory Hodgkin's diseaseTreatment-related mortalityDose-finding studyAssessable patientsAcceptable toxicityConditioning regimenInterstitial pneumonitisHodgkin's diseaseResidual diseaseHodgkin's lymphomaPatient populationDisease progressionHigh dosePatientsLymphomaDiseaseCBVDepletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Progress In Clinical And Biological Research 1990, 333: 207-15. PMID: 1689852.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, MonoclonalAntigens, CDAntigens, DifferentiationBone MarrowBone Marrow CellsBone Marrow TransplantationCD5 AntigensChildChild, PreschoolCombined Modality TherapyCyclophosphamideCytarabineDrug EvaluationGraft vs Host DiseaseHumansImmunotoxinsLeukemiaMiddle AgedMyelodysplastic SyndromesRicinRisk FactorsT-LymphocytesWhole-Body Irradiation
1989
Monoclonal and oligoclonal gammopathy after bone marrow transplantation.
Mitus A, Stein R, Rappeport J, Antin J, Weinstein H, Alper C, Smith B. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood 1989, 74: 2764-8. PMID: 2819246, DOI: 10.1182/blood.v74.8.2764.bloodjournal7482764.Peer-Reviewed Original ResearchMeSH KeywordsB-LymphocytesBone Marrow TransplantationGraft vs Host DiseaseHumansHypergammaglobulinemiaLymphoproliferative DisordersMonoclonal Gammopathy of Undetermined SignificanceTime FactorsConceptsBone marrow transplantationMonoclonal gammopathyMarrow transplantationSyngeneic bone marrow transplantationM-componentEarly B cell ontogenySerum protein electrophoresesSyngeneic graft recipientsT lymphocyte subsetsDevelopment of graftImmunoglobulin G typeB cell populationsOligoclonal gammopathyPatients posttransplantationDays posttransplantationHost diseaseGraft recipientsB cell ontogenyGammopathyTransplantationPosttransplantationPatientsUbiquitous findingCorrelation of recoveryG-typeA large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation.
Bierer B, Burakoff S, Smith B. A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation. Blood 1989, 73: 1359-66. PMID: 2467708, DOI: 10.1182/blood.v73.5.1359.bloodjournal7351359.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAntigens, DifferentiationAntigens, Differentiation, T-LymphocyteBone Marrow TransplantationCalciumCD3 ComplexCD5 AntigensCytoplasmCytotoxicity, ImmunologicGraft vs Host DiseaseHumansImmunologic Deficiency SyndromesInterleukin-2Leukocyte CountMicePhenotypeReceptors, Antigen, T-CellT-Lymphocytes, CytotoxicConceptsBone marrow transplantationCD5 expressionMarrow transplantationT cellsAllogeneic bone marrow transplantationFrequency of CD3Major histocompatibility complex compatibilityT-cell depletionPercent of CD8Expression of CD5Presence of graftBMT patientsTotal CD3Host diseaseInterstitial pneumonitisPreparative regimenPeripheral bloodT lymphocytesB cellsCD3Lectin stimulationPatientsNormal populationTransplantationCD5
1988
REGULATION OF CYTOTOXIC T LYMPHOCYTE-MEDIATED GRAFT REJECTION FOLLOWING BONE MARROW
Bierer B, Emerson S, Antin J, Maziarz R, Rappeport J, Smith B, Burakoff A. REGULATION OF CYTOTOXIC T LYMPHOCYTE-MEDIATED GRAFT REJECTION FOLLOWING BONE MARROW. Transplantation 1988, 46: 835-839. PMID: 3061078, DOI: 10.1097/00007890-198812000-00009.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntibodies, MonoclonalAntigens, Differentiation, T-LymphocyteBone Marrow TransplantationCells, CulturedCytotoxicity, ImmunologicGraft RejectionHumansMaleT-Lymphocytes, CytotoxicConceptsGraft rejectionHuman allogeneic bone marrow transplantationT cell-depleted marrowAllogeneic bone marrow transplantationClass I major histocompatibility complex antigensMajor histocompatibility complex antigensLymphocyte function-associated antigen-1Bone marrow transplantationFunction-associated antigen-1Cytotoxic T lymphocytesAnti-CD3 mAbHistocompatibility complex antigensBone marrow progenitor cellsMHC class IMarrow progenitor cellsNumber of mAbsBMT patientsCTL activityEffector cellsMarrow transplantationRecipient originT cellsT lymphocytesComplex antigensBone marrow
1987
Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients.
Daley J, Rozans M, Smith B, Burakoff S, Rappeport J, Miller R. Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients. Blood 1987, 70: 960-4. PMID: 3307954, DOI: 10.1182/blood.v70.4.960.bloodjournal704960.Peer-Reviewed Original ResearchMeSH KeywordsBone Marrow CellsBone Marrow TransplantationCell DivisionHumansLymphocyte DepletionPostoperative PeriodT-LymphocytesT-Lymphocytes, CytotoxicTime FactorsConceptsT cell-depleted bone marrowT cell frequenciesUntreated marrowT cellsBone marrowCell frequencyFunctional T cell compartmentBone marrow transplant recipientsDonor T cellsMonoclonal antibodies Leu-1Marrow transplant recipientsReactive T cellsT cell compartmentT lymphocyte precursorsCompetent T lymphocytesTransplant recipientsMarrow transplantationT lymphocytesLymphocyte precursorsLeu-1Neoplastic cellsMarrowPatientsRecipientsTransplantationB lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes.
Antin JH, Ault KA, Rappeport JM, Smith BR. B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. Journal Of Clinical Investigation 1987, 80: 325-332. PMID: 3112184, PMCID: PMC442241, DOI: 10.1172/jci113076.Peer-Reviewed Original ResearchConceptsLeu-1B cellsMarrow transplantationHuman bone marrow transplantationEffect of GVHDHuman marrow transplantationBone marrow transplantationEx vivo treatmentInterleukin-2 receptorB lymphocyte reconstitutionSeparate B cell lineageNormal B cellsB-cell lineageAcute GVHDChronic graftHost diseaseLymphocyte reconstitutionDonor originVivo treatmentB lymphocytesMultivariate analysisStages of differentiationGVHDTransplantationMarrow
1986
FUNCTIONAL ASSESSMENT OF T CELL DEPLETION FROM BONE MARROW PRIOR TO THERAPEUTIC TRANSPLANTATION USING LIMITING DILUTION CULTURE METHODS
Rozans M, Smith B, Emerson S, Crimmins M, Laurent G, Reichert T, Burakoff S, Miller R. FUNCTIONAL ASSESSMENT OF T CELL DEPLETION FROM BONE MARROW PRIOR TO THERAPEUTIC TRANSPLANTATION USING LIMITING DILUTION CULTURE METHODS. Transplantation 1986, 42: 380-386. PMID: 3094209, DOI: 10.1097/00007890-198610000-00010.Peer-Reviewed Original ResearchConceptsT-cell depletionT cellsComplement-mediated depletionCell depletionFACS analysisIL-2Functional impairmentT-lymphocyte depletionT-cell contaminationBone marrow inoculumT cell setsComplement-mediated lysisDilution methodFlow cytometric methodLymphocyte depletionComplement treatmentMarrow inoculumCytotoxic effectorsInterleukin-2Functional assessmentT101 immunotoxinCulture methodCytometric methodCell contaminationEventual deathLong-lasting deficit of functional T cell precursors in human bone marrow transplant recipients revealed by limiting dilution methods.
Rozans MK, Smith BR, Burakoff SJ, Miller RA. Long-lasting deficit of functional T cell precursors in human bone marrow transplant recipients revealed by limiting dilution methods. The Journal Of Immunology 1986, 136: 4040-8. PMID: 2939139, DOI: 10.4049/jimmunol.136.11.4040.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBone Marrow TransplantationChildChild, PreschoolClone CellsFlow CytometryHematopoietic Stem CellsHumansImmunologic Deficiency SyndromesInfantInfant, NewbornInterleukin-2Leukocyte CountLymphocyte ActivationLymphocyte Culture Test, MixedT-LymphocytesT-Lymphocytes, CytotoxicT-Lymphocytes, Helper-InducerTime FactorsConceptsBone marrow transplantationBMT patientsHuman bone marrow transplant recipientsAllogeneic bone marrow transplantationBone marrow transplant recipientsNormal levelsResidual immune dysfunctionT cell frequenciesMarrow transplant recipientsDilution methodT cell precursorsNear-normal levelsTransplant recipientsBMT recipientsImmune dysfunctionMarrow transplantationPrecursor frequencyLeu-3Immune functionNormal controlsPatientsLeu-2Cell frequencyDecreased frequencyCell precursorsThe physician's influence on informed consent for bone marrow transplantation
Patenaude A, Rappeport J, Smith B. The physician's influence on informed consent for bone marrow transplantation. Theoretical Medicine And Bioethics 1986, 7: 165-179. PMID: 3526626, DOI: 10.1007/bf00489228.Peer-Reviewed Original ResearchConceptsSpecial ethical issuesInformed consent discussionEthical conflictsEthical issuesQuestions of competencyBone marrow transplantationConscientious physicianInformed consentConsent discussionTheoretical goalMarrow transplantationConsentRelated bone marrow donorBone marrow donorsPhysician's discretionPrior relationshipVoluntarinessPatient anxietyPhysician judgmentMarrow donorsMedical alternativesPhysician influencePatientsDiscretionJudgmentsHTLV-III infection after bone marrow transplantation.
Antin JH, Smith BR, Ewenstein BM, Arceci RJ, Lipton JM, Page PL, Rappeport JM. HTLV-III infection after bone marrow transplantation. Blood 1986, 67: 160-3. PMID: 3000475, DOI: 10.1182/blood.v67.1.160.bloodjournal671160.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultBone Marrow TransplantationDeltaretrovirusHumansMalePostoperative ComplicationsRetroviridae InfectionsT-LymphocytesTransfusion ReactionConceptsGraft-v-host diseaseHTLV-III infectionBone marrow transplantationHTLV-IIIMarrow transplantationChronic graft-v-host diseaseBone marrow transplant recipientsAcquisition of antibodiesChronic GVHD diseaseLate opportunistic infectionsLoss of immunocompetenceOnly risk factorMarrow transplant recipientsPeripheral blood lymphocytesTransfusion-associated AIDSGVHD diseaseLymphocyte phenotypingHost diseaseTransplant recipientsImmunodeficiency syndromeOpportunistic infectionsAsymptomatic individualsPatient's immunodeficiencyRisk factorsSevere immunodeficiency
1985
Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment.
Antin JH, Ginsburg D, Smith BR, Nathan DG, Orkin SH, Rappeport JM. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood 1985, 66: 1247-50. PMID: 3904867, DOI: 10.1182/blood.v66.6.1247.bloodjournal6661247.Peer-Reviewed Original ResearchConceptsParoxysmal nocturnal hemoglobinuriaBone marrow transplantationConditioning regimenMarrow transplantationMarrow aplasiaPNH cloneNocturnal hemoglobinuriaPretransplant conditioning regimenCurative therapyAntithymocyte serumComplete engraftmentMarrow graftingSuccessful treatmentAbnormal clonePatientsHematopoietic stem cellsRBC typingTransplantationRegimenCell linesAplasiaDNA sequence polymorphism analysisEngraftmentHemoglobinuriaStem cellsPhenotype of recovering lymphoid cell populations after marrow transplantation.
Ault KA, Antin JH, Ginsburg D, Orkin SH, Rappeport JM, Keohan ML, Martin P, Smith BR. Phenotype of recovering lymphoid cell populations after marrow transplantation. Journal Of Experimental Medicine 1985, 161: 1483-1502. PMID: 3159819, PMCID: PMC2187630, DOI: 10.1084/jem.161.6.1483.Peer-Reviewed Original ResearchEFFICACY OF A CYCLOPHOSPHAMIDE-PROCARBAZINE-ANTITHYMOCYTE SERUM REGIMEN FOR PREVENTION OF GRAFT REJECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR TRANSFUSED PATIENTS WITH APLASTIC ANEMIA
Smith BR, Guinan EC, Parkman R, Ferrara J, Levey RH, Nathan DG, Rappeport JM. EFFICACY OF A CYCLOPHOSPHAMIDE-PROCARBAZINE-ANTITHYMOCYTE SERUM REGIMEN FOR PREVENTION OF GRAFT REJECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR TRANSFUSED PATIENTS WITH APLASTIC ANEMIA. Transplantation 1985, 39: 671-672. PMID: 3890295, DOI: 10.1097/00007890-198506000-00020.Peer-Reviewed Original ResearchIsolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes.
First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood 1985, 65: 368-74. PMID: 3881142, DOI: 10.1182/blood.v65.2.368.bloodjournal652368.Peer-Reviewed Original ResearchConceptsBone marrow transplantationMarrow transplantationThrombocytopenic syndromesChronic GVHDIsolated thrombocytopeniaPlatelet countThrombocytopenic patientsTransient thrombocytopeniaAllogeneic bone marrow transplantationSevere acute graftTrimethoprim-sulfamethoxazole administrationPeripheral platelet destructionTotal body irradiationBone marrow biopsyNormal platelet countAdverse patient prognosisNumber of megakaryocytesAcute graftIneffective thrombopoiesisPretransplant preparationHost diseasePreparatory regimensBody irradiationPlatelet destructionPlatelet precursorsOrigin of cell populations after bone marrow transplantation. Analysis using DNA sequence polymorphisms.
Ginsburg D, Antin JH, Smith BR, Orkin SH, Rappeport JM. Origin of cell populations after bone marrow transplantation. Analysis using DNA sequence polymorphisms. Journal Of Clinical Investigation 1985, 75: 596-603. PMID: 3882761, PMCID: PMC423535, DOI: 10.1172/jci111736.Peer-Reviewed Original ResearchMeSH KeywordsAdultBase SequenceBone Marrow TransplantationChildChimeraCloning, MolecularDNAFemaleGraft RejectionHematopoietic SystemHumansInfantLymphoid TissueMalePolymorphism, GeneticConceptsBone marrow transplantationMixed lymphohematopoietic chimerismMarrow transplantationFull engraftmentLeukemic relapseLymphohematopoietic chimerismDonor originSuccessful bone marrow transplantationSevere combined immunodeficiency syndromeFailure of engraftmentCombined immunodeficiency syndromeCell populationsParticular clinical valueDNA sequence polymorphism analysisHost originPatient's peripheral leukocytesGraft lossDonor marrowImmunodeficiency syndromePosttransplant lymphomaSuccessful engraftmentT cellsPolymorphism analysisPeripheral leukocytesClinical value
1984
Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation.
Parkman R, Rappeport JM, Hellman S, Lipton J, Smith B, Geha R, Nathan DG. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation. Blood 1984, 64: 852-7. PMID: 6383499, DOI: 10.1182/blood.v64.4.852.bloodjournal644852.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone Marrow DiseasesBone Marrow TransplantationBusulfanChildChild, PreschoolFemaleHematopoiesisHistocompatibilityHumansInfantMaleWhole-Body IrradiationConceptsTotal body irradiationBone marrow transplantationBone marrow disordersBody irradiationPreparation of patientsMarrow transplantationMarrow disordersInterstitial pneumonitisAllogeneic bone marrow transplantationAllogenic bone marrow transplantationIdiopathic interstitial pneumonitisCell agentsPreparatory regimenBusulfanPatientsHematopoietic stem cellsTransplantationTransplantPneumonitisDisordersHematopoietic ablationStem cellsRegimenRegimensAgents